OpGen Reports Third Quarter 2021 Financial Results and Provides Business Update
11 nov. 2021 16h05 HE
|
OpGen, Inc.
Total Revenue for Q3 2021 was approximately $1.2 millionCash as of September 30, 2021, was approximately $25.4 million, up significantly from the $13.4 million at year-end 2020Cash balance was further...
OpGen Announces Special Meeting of Stockholders to Vote on Proposed Increase to Number of Authorized Shares of Common Stock
04 nov. 2021 07h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to...
OpGen Appoints Albert Weber as Chief Financial Officer
04 nov. 2021 07h30 HE
|
OpGen, Inc.
Albert Weber to join OpGen as OpGen’s CFO effective January 1, 2022 from U.S.-German molecular diagnostics company EpigenomicsAnnounces inducement grant of 210,000 stock options under NASDAQ Listing...
OpGen to Provide Business Update and Financial Results for the Third Quarter 2021 on November 11th at 4:30 p.m. Eastern Time
28 oct. 2021 07h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., Oct. 28, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter...
OpGen Subsidiary Ares Genetics Launches AREScloud
21 oct. 2021 07h30 HE
|
OpGen, Inc.
AREScloud is a new, commercial web application aimed at accelerating the analysis of sequenced clinical isolatesAREScloud offers an advanced solution for infection prevention and control ROCKVILLE,...
OpGen Announces Closing of $15 Million Registered Direct Offering
18 oct. 2021 16h30 HE
|
OpGen, Inc.
ROCKVILLE, Md., Oct. 18, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...
OpGen Announces $15 Million Registered Direct Offering
14 oct. 2021 08h00 HE
|
OpGen, Inc.
ROCKVILLE, Md., Oct. 14, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics...
OpGen Provides Business Update and Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2021
04 oct. 2021 07h30 HE
|
OpGen, Inc.
Preliminary Total Revenue for Q3 2021 was approximately $1.2 millionCash as of September 30, 2021 was approximately $25.4 million, up significantly from the $13.4 million at year-end 2020OpGen...
OpGen Receives FDA Clearance for Acuitas® AMR Gene Panel
04 oct. 2021 07h30 HE
|
OpGen, Inc.
OpGen’s Acuitas® AMR Gene Panel allows testing for a comprehensive panel of 28 genetic AMR markers in isolated bacterial colonies from 26 different pathogensAn aid to clinicians in the management of...
OpGen Initiates Clinical Trial for Unyvero Urinary Tract Infection Panel
30 sept. 2021 07h30 HE
|
OpGen, Inc.
OpGen’s Unyvero Urinary Tract Infection (UTI) Panel tests for a broad range of pathogens as well as antimicrobial resistance markers directly from native urine specimensProspective multicenter trial...